FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2415-2418 June 7, 2007 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Terzolo, M. PubMed Citation

Adrenocortical carcinoma is a rare, highly malignant neoplasm with an incidence of 2 cases per 1 million population per year worldwide, representing 0.2% of all cases of cancer. Several treatment strategies in patients with advanced disease have resulted in temporary or partial tumor regression, yet very few patients attain long-term survival. Assessing the effectiveness of most published treatment protocols has been difficult, since most series have been limited by the inclusion of relatively few subjects, with tumors at various stages and grades. Several drug regimens have been used, and multiple treatments have been administered in various sequences. In addition, the . . . [Full Text of this Article]

Source Information

From the Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical Center, Ann Arbor.

Related Letters:

Adjuvant Mitotane in Adrenocortical Carcinoma
Bertherat J., Coste J., Bertagna X., Dickstein G., Shechner C., Nativ O., Lee J. E., Machens A., Dralle H., Terzolo M., Fassnacht M., Berruti A.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1256-1259, Sep 20, 2007. Correspondence

This article has been cited by other articles:

• Terzolo, M., Fassnacht, M., Ciccone, G., Allolio, B., Berruti, A. (2009). Adjuvant Mitotane for Adrenocortical Cancer--Working through Uncertainty. J. Clin. Endocrinol. Metab. 94: 1879-1880 [Full Text]  
• de Reynies, A., Assie, G., Rickman, D. S., Tissier, F., Groussin, L., Rene-Corail, F., Dousset, B., Bertagna, X., Clauser, E., Bertherat, J. (2009). Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival. JCO 27: 1108-1115 [Abstract] [Full Text]  
• Barlaskar, F. M., Spalding, A. C., Heaton, J. H., Kuick, R., Kim, A. C., Thomas, D. G., Giordano, T. J., Ben-Josef, E., Hammer, G. D. (2009). Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma. J. Clin. Endocrinol. Metab. 94: 204-212 [Abstract] [Full Text]  
• Daffara, F., De Francia, S., Reimondo, G., Zaggia, B., Aroasio, E., Porpiglia, F., Volante, M., Termine, A., Di Carlo, F., Dogliotti, L., Angeli, A., Berruti, A., Terzolo, M. (2008). Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15: 1043-1053 [Abstract] [Full Text]  
• Bertherat, J., Coste, J., Bertagna, X., Dickstein, G., Shechner, C., Nativ, O., Lee, J. E., Machens, A., Dralle, H., Terzolo, M., Fassnacht, M., Berruti, A. (2007). Adjuvant Mitotane in Adrenocortical Carcinoma. NEJM 357: 1256-1259 [Full Text]  
• (2007). Adjuvant Therapy for Adrenal Cancer. JWatch Oncology and Hematology 2007: 1-1 [Full Text]